- Home
- IBIO vs NRXS Comparison
IBIO vs NRXS Comparison
Compare IBIO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBIO | NRXS |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 46.3M |
| IPO Year | 2009 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IBIO | NRXS |
|---|---|---|
| Price | $2.39 | $6.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 113.9K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | 72.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,685,925.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $146.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 9.18 |
| 52 Week Low | $0.56 | $1.33 |
| 52 Week High | $5.85 | $6.35 |
Technical Indicators
Market Signals| Indicator | IBIO | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 64.37 |
| Support Level | $2.02 | $2.32 |
| Resistance Level | $3.01 | $6.20 |
| Average True Range (ATR) | 0.25 | 0.46 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 12.50 | 76.00 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).